Kintara Therapeutics (KTRA)
(Delayed Data from NSDQ)
$0.17 USD
-0.01 (-4.24%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.17 0.00 (-2.30%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Kintara Therapeutics, Inc falls in the month of June .
All items in Millions except EPS data.
6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | |
---|---|---|---|---|---|
Sales | NA | 0 | 0 | 0 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 15 | 23 | 38 | 9 |
Income After Depreciation & Amortization | 0 | -15 | -23 | -38 | -9 |
Non-Operating Income | NA | 0 | 0 | 0 | 0 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -15 | -23 | -38 | -9 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -15 | -23 | -38 | -9 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -15 | -23 | -38 | -9 |
Depreciation Footnote | 6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -12 | -23 | -38 | -9 |
Depreciation & Amortization (Cash Flow) | NA | 3 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -15 | -23 | -38 | -9 |
Earnings Per Share Data | 6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 |
---|---|---|---|---|---|
Average Shares | NA | 1.62 | 0.97 | 0.52 | 0.21 |
Diluted EPS Before Non-Recurring Items | NA | -9.27 | -26.00 | -80.00 | -38.50 |
Diluted Net EPS (GAAP) | NA | -9.27 | -26.00 | -80.00 | -43.50 |
Fiscal Year end for Kintara Therapeutics, Inc falls in the month of June .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2.08 | 1.02 | 2.96 | 3.35 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -2.08 | -1.02 | -2.96 | -3.35 |
Non-Operating Income | NA | 0.07 | 0.00 | 0.00 | 0.05 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.04 |
Pretax Income | NA | -2.01 | -1.02 | -2.96 | -3.34 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -2.01 | -1.02 | -2.96 | -3.34 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.01 | -1.02 | -2.96 | -3.34 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 44.56 | 4.34 | 1.72 | 1.71 |
Diluted EPS Before Non-Recurring Items | NA | -0.05 | -0.24 | -1.83 | -1.95 |
Diluted Net EPS (GAAP) | NA | -0.05 | -0.24 | -1.83 | -1.73 |